India’s 30% Cancer Drug Trade Margin Cap: What Patients Need to Know
The Indian government has approved a measure to limit trade margins on non-scheduled anti-cancer medicines to 30% of their maximum retail price (MRP), seeking to reduce the cost of cancer treatment for patients. Announced on October 8, 2026, the policy could lower the retail prices of some medicines by up to 70% and generate estimated annual savings of ₹2,500 crore.
The decision addresses a longstanding concern in India’s pharmaceutical market: the substantial difference between the prices at which medicines enter the distribution chain and the amounts patients ultimately pay. However, the extent of the benefit will depend on which medicines are covered, how the rules are implemented and whether the price reductions reach patients.
Why India Is Changing Cancer Drug Pricing Rules
Cancer treatment can place a considerable financial burden on families, particularly when patients require expensive medicines over extended periods. Alongside the cost of drugs, households may need to pay for hospital visits, diagnostic tests, surgery, radiation therapy and other medical services.
The National Pharmaceutical Pricing Authority (NPPA) has examined the mark-ups applied to non-scheduled cancer medicines. According to reporting on the government’s decision, the analysis found average trade mark-ups of approximately 170%, with some reportedly reaching 700%.
These figures have brought attention to the role of pricing throughout the pharmaceutical supply chain, including manufacturers, distributors, wholesalers and retailers.
The new measure aims to restrict excessive trade margins on selected medicines and improve affordability without disrupting their availability.
Which Medicines Will Be Covered?
The initial list is expected to include around 110 non-scheduled anti-cancer medicines, including approximately 35 patented drugs, according to reporting by Business Standard.
The proposed coverage includes branded and generic medicines, as well as domestically manufactured and imported products. The expert committee under the Directorate General of Health Services is responsible for finalising the list of medicines covered by the policy.
The distinction between scheduled and non-scheduled medicines is important. Scheduled formulations already have government-fixed ceiling prices under existing price-control rules. Non-scheduled medicines fall outside that particular list, although they may still be subject to other applicable regulations.
The new decision extends price protection to additional cancer medicines. The final notified list will determine which specific products are covered.
Could Cancer Drug Prices Fall by 70%?
The government estimates that the measure could reduce the prices of some affected medicines by as much as 70%. It also projects annual savings of approximately ₹2,500 crore for cancer patients.
These figures are estimates, not guaranteed reductions for every medicine. The actual change will depend on the existing price, the trade margins currently applied and the way the new restrictions affect each product.
A medicine with unusually high mark-ups could see a substantial reduction, while another product may experience a smaller change. Patients should therefore check the revised price of their prescribed medicine rather than assume that every cancer drug will become 70% cheaper.
The government’s broader objective is to reduce out-of-pocket expenditure while maintaining access to essential treatment.
Why the Supreme Court Has Raised Wider Concerns
The debate over medicine affordability has also reached the Supreme Court of India. On October 12, the court questioned whether action against excessive medicine mark-ups should be confined to cancer drugs or expanded to other medicines and medical devices.
The proceedings brought wider pharmaceutical pricing practices into focus, including concerns about large differences between procurement costs and the prices charged to consumers.
The court’s intervention raises a broader policy question: whether existing price-control mechanisms adequately address affordability across the healthcare system.
The cancer medicine measure is one part of that discussion. Any extension to other medicines or medical devices would require further government action and clarification of the applicable rules.
What the Policy Means for Patients and Pharmaceutical Companies
For patients, lower retail prices could reduce the financial pressure associated with certain cancer treatments. Savings may be particularly significant for people who need expensive medicines repeatedly or over long treatment periods.
For pharmaceutical companies and distributors, the restrictions could require changes to pricing and distribution practices. Regulators will need to monitor compliance and ensure that lower prices do not lead to avoidable supply shortages.
The policy’s effectiveness will depend on more than the announcement itself. Patients must be able to identify covered medicines, verify the applicable prices and obtain their prescribed treatments reliably.
Patients should continue following their oncologists’ advice and confirm medicine prices and availability with licensed pharmacies or their treating hospitals.
What Happens Next?
The expert committee is expected to finalise the medicines covered by the margin cap, with the government’s formal notification and implementation details determining how the rules apply to individual products.
The Supreme Court’s next scheduled consideration of the wider medicine-pricing issue is October 27, 2026. Further developments may clarify whether additional action is considered beyond cancer medicines.
The key indicators will be the final list of covered drugs, revised retail prices, compliance across the supply chain and the continued availability of treatment.
TVR Perspective
Restricting excessive trade margins could make selected cancer medicines more affordable, but the real test is what patients pay at the pharmacy. Transparent price information, consistent enforcement and reliable supplies will be essential to achieving the intended savings. The wider debate before the Supreme Court also highlights the need to examine medicine affordability across healthcare, rather than treating cancer drug pricing as an isolated concern.
Sources & Verification
Department of Pharmaceuticals — Government expands cancer medicine price controls
Business Standard — Centre to cap trade margins on non-scheduled cancer drugs at 30%
The Economic Times — Expert panel to finalise cancer drugs covered by the margin cap
The Indian Express — How the cancer drug price-control proposal works
About TVR
TVR: The Voice Of Reform is an independent digital news platform covering major developments across India and around the world.
Editorial Note
Our articles are prepared using publicly available information and verified reporting. We aim to present news accurately, independently and responsibly. Information may be updated as new facts emerge.
© 2026 TVR: The Voice Of Reform. All Rights Reserved.

Comments